More patients opt for mastectomy despite limited, early-stage breast cancer
the ONA take:
According to a new study published in JAMA Surgey, researchers from Vanderbilt University in Nashville, Tennessee, have found that more women with breast cancer are opting for mastectomy, including double mastectomy, rather than undergoing breast conservation surgery despite having early stage disease that is limited to one breast.
For the study, researchers analyzed the records of more than 1.2 million adults women with breast cancer treated from 1998 to 2011 from the National Cancer Data Base. Of those, 35.5% underwent a mastectomy. In the 8 most recent years of the study, the odds of breast conversation surgery-eligible women opting for mastectomy increased 34%.
During the entire period of the study, the rate of double mastectomy in women with cancer in only one breast increased from 1.9% to 11.2%. During the same period, the rate of breast reconstruction in women who underwent mastectomy increased from 11.6% to 36.4%.
The researchers note that the rising rate of mastectomy was most marked among younger women with noninvasive disease, women with smaller tumors, and women with node-negative disease. The findings suggest that factors other than disease burden and cancer control are influencing women to undergo mastectomy.
More women with breast cancer are opting for mastectomy rather than undergoing breast conservation surgery.
The rates of increase were steepest among women with lymph node-negative and in situ (contained) disease. This is a reversal of trends seen since the 1990s when breast conservation surgery (BCS) was found to produce equivalent cancer outcomes and was endorsed as a standard of excellence by a National Institutes of Health Consensus Conference.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient Selection
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|